within Pharmacolibrary.Drugs.ATC.L;

model L01BC03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.425,
    Cl             = 6.4e-05,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0145,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010333333333333333,
    Tlag           = 13.2,            
    Vdp             = 0.00684,
    k12             = 6.65,
    k21             = 6.65
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BC03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tegafur is an anticancer prodrug of 5-fluorouracil (5-FU), typically used in combination with other agents such as uracil or gimeracil/oteracil (as UFT or S-1 formulations) for the oral treatment of various solid tumors, including gastrointestinal cancers. While tegafur is not widely used as monotherapy today, its combinational forms remain approved and in clinical use, primarily in Asia.</p><h4>Pharmacokinetics</h4><p>Mean (± SD) pharmacokinetic parameters in adult Japanese cancer patients given oral tegafur 400 mg.</p><h4>References</h4><ol><li><p>Wellington, K, &amp; Goa, KL (2001). Oral tegafur/uracil. <i>Drugs &amp; aging</i> 18(12) 935–950. DOI:<a href=&quot;https://doi.org/10.2165/00002512-200118120-00005&quot;>10.2165/00002512-200118120-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11888348/&quot;>https://pubmed.ncbi.nlm.nih.gov/11888348</a></p></li><li><p>Kobuchi, S, et al., &amp; Sakaeda, T (2018). Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 123 452–458. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2018.08.004&quot;>10.1016/j.ejps.2018.08.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30077713/&quot;>https://pubmed.ncbi.nlm.nih.gov/30077713</a></p></li><li><p>Hirata, K, et al., &amp; Shirasaka, T (2006). [Pharmacokinetics of S-1]. <i>Gan to kagaku ryoho. Cancer &amp; chemotherapy</i> 33 Suppl 1 27–35. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16897969/&quot;>https://pubmed.ncbi.nlm.nih.gov/16897969</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BC03;
